77 related articles for article (PubMed ID: 10628332)
1. Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery.
Pellizzaro C; Coradini D; Morel S; Ugazio E; Gasco MR; Daidone MG
Anticancer Res; 1999; 19(5B):3921-5. PubMed ID: 10628332
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction.
Salomone B; Ponti R; Gasco MR; Ugazio E; Quaglino P; Osella-Abate S; Bernengo MG
Clin Exp Metastasis; 2000; 18(8):663-73. PubMed ID: 11827070
[TBL] [Abstract][Full Text] [Related]
3. The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation.
Ugazio E; Marengo E; Pellizzaro C; Coradini D; Peira E; Daidone MG; Gasco MR
Eur J Pharm Biopharm; 2001 Sep; 52(2):197-202. PubMed ID: 11522486
[TBL] [Abstract][Full Text] [Related]
4. Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells.
Dianzani C; Cavalli R; Zara GP; Gallicchio M; Lombardi G; Gasco MR; Panzanelli P; Fantozzi R
Br J Pharmacol; 2006 Jul; 148(5):648-56. PubMed ID: 16702992
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.
Serpe L; Catalano MG; Cavalli R; Ugazio E; Bosco O; Canaparo R; Muntoni E; Frairia R; Gasco MR; Eandi M; Zara GP
Eur J Pharm Biopharm; 2004 Nov; 58(3):673-80. PubMed ID: 15451544
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles.
Lee MK; Lim SJ; Kim CK
Biomaterials; 2007 Apr; 28(12):2137-46. PubMed ID: 17257668
[TBL] [Abstract][Full Text] [Related]
7. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells.
Choi SH; Jin SE; Lee MK; Lim SJ; Park JS; Kim BG; Ahn WS; Kim CK
Eur J Pharm Biopharm; 2008 Mar; 68(3):545-54. PubMed ID: 17881199
[TBL] [Abstract][Full Text] [Related]
8. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
Attama AA; Müller-Goymann CC
Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells.
Serpe L; Laurora S; Pizzimenti S; Ugazio E; Ponti R; Canaparo R; Briatore F; Barrera G; Gasco MR; Bernengo MG; Eandi M; Zara GP
Anticancer Drugs; 2004 Jun; 15(5):525-36. PubMed ID: 15166628
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation, invasion and adhesion of liver cancer cells by 5-azacytidine and butyrate.
Wang XM; Li J; Evers BM
Anticancer Res; 1999; 19(4B):2901-6. PubMed ID: 10652571
[TBL] [Abstract][Full Text] [Related]
11. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization.
Liu J; Gong T; Wang C; Zhong Z; Zhang Z
Int J Pharm; 2007 Aug; 340(1-2):153-62. PubMed ID: 17428627
[TBL] [Abstract][Full Text] [Related]
12. Modulation of lipid synthesis, apolipoprotein biogenesis, and lipoprotein assembly by butyrate.
Marcil V; Delvin E; Seidman E; Poitras L; Zoltowska M; Garofalo C; Levy E
Am J Physiol Gastrointest Liver Physiol; 2002 Aug; 283(2):G340-6. PubMed ID: 12121881
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
14. Solid lipid nanoparticles for parenteral drug delivery.
Wissing SA; Kayser O; Müller RH
Adv Drug Deliv Rev; 2004 May; 56(9):1257-72. PubMed ID: 15109768
[TBL] [Abstract][Full Text] [Related]
15. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
Cho Y; Park MJ; Park M; Min SS; Yee J; Kim C; Han MS; Han SH
Respirology; 2009 Aug; 14(6):850-8. PubMed ID: 19703066
[TBL] [Abstract][Full Text] [Related]
16. Derivatives of butyric acid as potential anti-neoplastic agents.
Rephaeli A; Rabizadeh E; Aviram A; Shaklai M; Ruse M; Nudelman A
Int J Cancer; 1991 Aug; 49(1):66-72. PubMed ID: 1874573
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.
Davis T; Kennedy C; Chiew YE; Clarke CL; deFazio A
Clin Cancer Res; 2000 Nov; 6(11):4334-42. PubMed ID: 11106251
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.
Pellizzaro C; Speranza A; Zorzet S; Crucil I; Sava G; Scarlata I; Cantoni S; Fedeli M; Coradini D
Pancreas; 2008 May; 36(4):e15-23. PubMed ID: 18437074
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
20. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells.
Sharma G; Singh RP; Chan DC; Agarwal R
Anticancer Res; 2003; 23(3B):2649-55. PubMed ID: 12894553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
